Phase 2 × INDUSTRY × Immune System Diseases × Clear all
NCT07216443 2026-02-23

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Orca Biosystems, Inc.

Phase 2 Recruiting
80 enrolled
NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Pfizer

Phase 2 Completed
39 enrolled 15 charts
NCT04996875 2025-05-30

APEX

Cogent Biosciences, Inc.

Phase 2 Recruiting
140 enrolled
NCT03744676 2025-02-27

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Juno Therapeutics, a Subsidiary of Celgene

Phase 2 Completed
104 enrolled 29 charts